What is the recommended dose of Valtrex (valacyclovir) for a herpes outbreak?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Valacyclovir (Valtrex) Dosing for Herpes Outbreaks

For oral herpes (cold sores), the recommended dose of valacyclovir is 2 grams twice daily for 1 day, taken 12 hours apart. 1, 2

Dosing Recommendations by Type of Herpes Outbreak

Oral Herpes (Cold Sores/Herpes Labialis)

  • 2 grams twice daily for 1 day, taken 12 hours apart 1, 2
  • Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning) 1
  • This short-course therapy has demonstrated significant reduction in episode duration compared to placebo 2

Genital Herpes

  • Initial episode: 1 gram twice daily for 10 days 1
  • Recurrent episodes: 500 mg twice daily for 5 days 1, 3
  • Suppressive therapy: 1 gram once daily for patients with normal immune function 1
  • For patients with 9 or fewer recurrences per year, an alternative suppressive dose is 500 mg once daily 1
  • For HIV-infected patients with CD4+ count ≥100 cells/mm³, the recommended suppressive dose is 500 mg twice daily 1

Timing of Treatment Initiation

  • Treatment should be initiated during the prodromal phase (when experiencing tingling, itching, or burning) or within 1 day after onset of lesions for maximum effectiveness 3
  • Early initiation of therapy during the prodromal phase may potentially prevent lesion development 2
  • Valacyclovir therapy is most effective when started at the earliest sign or symptom of an outbreak 1

Efficacy Considerations

  • Valacyclovir has enhanced absorption after oral administration compared to acyclovir 3
  • It can reduce the duration of symptoms, decrease pain associated with lesions, and accelerate healing time 3, 2
  • For oral herpes, valacyclovir treatment has shown a shorter median duration of episodes (4.0-5.0 days) compared to placebo 3, 2
  • For genital herpes, valacyclovir 500 mg twice daily for 5 days has been shown to be as effective as longer treatment regimens 4, 5

Special Considerations

  • For immunocompromised patients, standard dosing is typically used, but these patients should be monitored more closely 2
  • Valacyclovir is generally well-tolerated with common adverse events including headache, nausea, and gastrointestinal complaints 2, 6
  • No laboratory monitoring is needed in patients receiving therapy unless they have substantial renal impairment 7
  • Valacyclovir may be given without regard to meals 1

Common Pitfalls and Caveats

  • Valacyclovir 500 mg once daily appears less effective than other valacyclovir dosing regimens in patients who have very frequent recurrences (≥10 episodes per year) 4, 7
  • Suppressive treatment reduces but does not eliminate asymptomatic viral shedding 7
  • After 1 year of continuous suppressive therapy, discontinuation should be considered to assess the patient's rate of recurrent episodes, as recurrence frequency often decreases over time 4, 7
  • High-dose valacyclovir (8 g/day) has been associated with thrombotic thrombocytopenic purpura/hemolytic uremic syndrome, but this has not been reported at doses used for herpes suppression 7, 8

References

Guideline

Valacyclovir Treatment for Oral Herpes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Valacyclovir Treatment for Herpes Outbreaks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Valacyclovir. New indication: for genital herpes, simpler administration.

Canadian family physician Medecin de famille canadien, 1999

Guideline

Timing of Maximal Effect for Suppressive Therapy in Oral HSV-1

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.